688212 澳华内镜
盘后交易 10-14 15:00:00
资讯
新帖
简况
每周股票复盘：澳华内镜（688212）ERCP手术机器人国内多中心临床推进中
证券之星 · 09-20
每周股票复盘：澳华内镜（688212）ERCP手术机器人国内多中心临床推进中
澳华内镜：2026年第一次临时股东会决议公告
证券日报网 · 09-18
澳华内镜：2026年第一次临时股东会决议公告
澳华内镜：9月15日接受机构调研，富国基金、中哲物产投资等多家机构参与
证券之星 · 09-16
澳华内镜：9月15日接受机构调研，富国基金、中哲物产投资等多家机构参与
股市必读：澳华内镜新发布《关于使用部分超募资金永久补充流动资金的公告》
证券之星 · 08-31
股市必读：澳华内镜新发布《关于使用部分超募资金永久补充流动资金的公告》
每周股票复盘：澳华内镜（688212）募投项目结项节余4590万补流
证券之星 · 08-30
每周股票复盘：澳华内镜（688212）募投项目结项节余4590万补流
澳华内镜（688212）披露募投项目结项并将节余募集资金永久补充流动资金公告，8月28日股价上涨0.18%
证券之星 · 08-28
澳华内镜（688212）披露募投项目结项并将节余募集资金永久补充流动资金公告，8月28日股价上涨0.18%
每周股票复盘：澳华内镜（688212）股东户数增13.5%，中报净亏8562万
证券之星 · 08-23
每周股票复盘：澳华内镜（688212）股东户数增13.5%，中报净亏8562万
股市必读：澳华内镜中报 - 第二季度单季净利润同比下降411.00%
证券之星 · 08-21
股市必读：澳华内镜中报 - 第二季度单季净利润同比下降411.00%
图解澳华内镜中报：第二季度单季净利润同比下降411.00%
证券之星 · 08-20
图解澳华内镜中报：第二季度单季净利润同比下降411.00%
澳华内镜（688212）披露2026年半年度报告，8月19日股价下跌4.14%
证券之星 · 08-19
澳华内镜（688212）披露2026年半年度报告，8月19日股价下跌4.14%
8月12日澳华内镜涨6.68%，圆信永丰医药健康A基金重仓该股
证券之星 · 08-12
8月12日澳华内镜涨6.68%，圆信永丰医药健康A基金重仓该股
澳华内镜：ERCP手术机器人已进入创新医疗器械特别审查程序
证券之星 · 08-10
澳华内镜：ERCP手术机器人已进入创新医疗器械特别审查程序
澳华内镜获得发明专利授权：“力反馈调节装置”
证券之星 · 08-05
澳华内镜获得发明专利授权：“力反馈调节装置”
澳华内镜新注册《澳华AQ-400系列电子内窥镜系统软件V1.0》项目的软件著作权
证券之星 · 08-05
澳华内镜新注册《澳华AQ-400系列电子内窥镜系统软件V1.0》项目的软件著作权
澳华内镜新注册《澳华AQ-200系列电子内窥镜系统软件V1.1》等2个项目的软件著作权
证券之星 · 08-01
澳华内镜新注册《澳华AQ-200系列电子内窥镜系统软件V1.1》等2个项目的软件著作权
股市必读：澳华内镜（688212）7月22日董秘有最新回复
证券之星 · 07-23
股市必读：澳华内镜（688212）7月22日董秘有最新回复
澳华内镜创历史新低
格隆汇 · 07-22
澳华内镜创历史新低
7月17日澳华内镜跌7.46%，富国精准医疗混合A基金重仓该股
证券之星 · 07-17
7月17日澳华内镜跌7.46%，富国精准医疗混合A基金重仓该股
澳华内镜新注册《澳华电子内窥镜系统软件（AQ-120系列）V1.1》项目的软件著作权
证券之星 · 07-14
澳华内镜新注册《澳华电子内窥镜系统软件（AQ-120系列）V1.1》项目的软件著作权
澳华内镜新注册《澳华AQ-300系列电子内窥镜系统软件V1.1》等2个项目的软件著作权
证券之星 · 07-11
澳华内镜新注册《澳华AQ-300系列电子内窥镜系统软件V1.1》等2个项目的软件著作权
暂无数据
公司概况
公司名称：
上海澳华内镜股份有限公司
所属行业：
专用设备制造业
上市日期：
2021-11-15
主营业务：
上海澳华内镜股份有限公司的主营业务是电子内窥镜设备及内窥镜诊疗手术耗材研发、生产和销售。公司的主要产品是内镜主机（含图像处理器和光源）、内镜镜体、内镜周边设备、非血管支架、基础类耗材。
发行价格：
22.50
{"stockData":{"symbol":"688212","market":"SH","secType":"STK","nameCN":"澳华内镜","latestPrice":25.8,"timestamp":1791961200000,"preClose":26.37,"halted":0,"volume":1220867,"delay":0,"changeRate":-0.0216,"floatShares":135000000,"shares":135000000,"eps":-0.2481,"marketStatus":"盘后交易","change":-0.57,"latestTime":"10-14 15:00:00","open":26.42,"high":26.52,"low":25.6,"amount":31657200,"amplitude":0.0349,"askPrice":25.81,"askSize":20,"bidPrice":25.8,"bidSize":67,"shortable":0,"etf":0,"ttmEps":-0.2481,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792027800000},"marketStatusCode":4,"adr":0,"adjPreClose":26.37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791941400000,1791948600000],[1791954000000,1791961200000]],"highLimit":29.01,"lowLimit":23.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":134665250,"isCdr":false,"pbRate":2.84,"roa":"--","roe":"--","epsLYR":0.09,"committee":-0.042373,"marketValue":3474000000,"turnoverRate":0.0091,"status":1,"afterMarket":{"amount":0,"volume":0,"close":25.8,"buyVolume":0,"sellVolume":0,"time":1791962910746,"indexStatus":"盘后交易 10-14 15:28:30","preClose":26.37},"floatMarketCap":3474000000},"requestUrl":"/m/hq/s/688212/tweets","defaultTab":"tweets","newsList":[{"id":"2668909850","title":"每周股票复盘：澳华内镜（688212）ERCP手术机器人国内多中心临床推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2668909850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668909850?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:44","pubTimestamp":1789839852,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，澳华内镜报收于27.6元，较上周的27.9元下跌1.08%。本周关注点来自机构调研要点：ERCP手术机器人国内临床正于头部医院多中心同步推进。机构调研要点问：新产品ERCP手术机器人在国内市场最新的临床进展？整体包含基础ERCP手术操作费用、配套耗材费用以及后续机器人辅助操作相关医疗服务费用。ERCP手术机器人销售推广科室和现有软镜业务同属消化科，整体销售费用占营业收入的比例趋向可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668924889","title":"澳华内镜：2026年第一次临时股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2668924889","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668924889?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:06","pubTimestamp":1789736760,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月18日，澳华内镜发布公告称，公司于2026年9月18日召开2026年第一次临时股东会，审议通过《关于使用部分超募资金永久补充流动资金的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-18/doc-inishkur3087811.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-18/doc-inishkur3087811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667350986","title":"澳华内镜：9月15日接受机构调研，富国基金、中哲物产投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667350986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667350986?lang=zh_cn&edition=full","pubTime":"2026-09-16 21:09","pubTimestamp":1789564198,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月16日澳华内镜发布公告称公司于2026年9月15日接受机构调研，富国基金、中哲物产投资、华宝自营、国联基金、前海开源基金、贺腾资产、中域资产、睿扬投资、鹏华基金、国寿安保基金、杭银理财、长信基金、深圳茗辉基金、上海原点资产、DNB Carnegie、上海聂丰私募、中金资管、招银理财、金信基金、红塔红土参与。整体包含基础ERCP手术操作费用、配套耗材费用以及后续机器人辅助操作相关医疗服务费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600035915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663255800","title":"股市必读：澳华内镜新发布《关于使用部分超募资金永久补充流动资金的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663255800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663255800?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:20","pubTimestamp":1788139219,"startTime":"0","endTime":"0","summary":"公司公告汇总关于使用部分超募资金永久补充流动资金的公告上海澳华内镜股份有限公司拟使用575.00万元超募资金永久补充流动资金，占超募资金总额的29.98%。会议审议《关于使用部分超募资金永久补充流动资金的议案》，该议案对中小投资者单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100003545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043874","title":"每周股票复盘：澳华内镜（688212）募投项目结项节余4590万补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663043874?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:39","pubTimestamp":1788043149,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，澳华内镜报收于28.24元，较上周的28.27元下跌0.11%。本周，澳华内镜8月28日盘中最高价报29.05元。本周关注点来自公司公告汇总：募投项目“医用内窥镜生产基地建设项目”结项，节余募集资金4,590.48万元拟永久补充流动资金。公司公告汇总上海澳华内镜股份有限公司拟使用575.00万元超募资金永久补充流动资金，占超募资金总额的29.98%。保荐机构中信证券对该事项无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091551","title":"澳华内镜（688212）披露募投项目结项并将节余募集资金永久补充流动资金公告，8月28日股价上涨0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662091551?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:27","pubTimestamp":1787927246,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，澳华内镜报收于28.24元，较前一交易日上涨0.18%，最新总市值为38.03亿元。近日，澳华内镜披露《中信证券股份有限公司关于上海澳华内镜股份有限公司募投项目结项并将节余募集资金永久补充流动资金的核查意见》。公司拟将节余募集资金永久补充流动资金，用于日常生产经营，并注销相关募集资金专户。该事项已获董事会审议通过，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800054956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661110042","title":"每周股票复盘：澳华内镜（688212）股东户数增13.5%，中报净亏8562万","url":"https://stock-news.laohu8.com/highlight/detail?id=2661110042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661110042?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:59","pubTimestamp":1787425147,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，澳华内镜报收于28.27元，较上周的32.37元下跌12.67%。公司公告汇总：2026年上半年研发投入7,040.52万元，占营收比例25.19%，ERCP手术机器人进入国家创新医疗器械特别审查程序。股本股东变化截至2026年6月30日，澳华内镜股东户数为7,576.0户，较3月31日增加901.0户，增幅达13.5%。2026年上半年，公司持续推进全球化营销布局，新大楼已投入使用，发布多款新产品，ERCP手术机器人进入国家创新医疗器械特别审查程序，新增专利授权13项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661923173","title":"股市必读：澳华内镜中报 - 第二季度单季净利润同比下降411.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661923173","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661923173?lang=zh_cn&edition=full","pubTime":"2026-08-21 03:00","pubTimestamp":1787252440,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，澳华内镜报收于28.82元，下跌2.07%，换手率3.15%，成交量4.24万手，成交额1.23亿元。股本股东变化：截至2026年6月30日股东户数为7576.0户，较3月31日增加13.5%。业绩披露要点：2026年第二季度归母净利润为-6118.63万元，同比下降411.0%。公司公告汇总：公司计提2026年半年度资产减值准备共计1853.63万元，影响合并利润总额等额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100002111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660273824","title":"图解澳华内镜中报：第二季度单季净利润同比下降411.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660273824","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660273824?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:24","pubTimestamp":1787160275,"startTime":"0","endTime":"0","summary":"证券之星消息，澳华内镜2026年中报显示，上半年度公司主营收入2.8亿元，同比上升7.37%；归母净利润-8561.96万元，同比下降110.03%；扣非净利润-8805.85万元，同比下降70.15%；其中2026年第二季度，公司单季度主营收入1.42亿元，同比上升3.96%；单季度归母净利润-6118.63万元，同比下降411.0%；单季度扣非净利润-6124.24万元，同比下降195.09%；负债率36.13%，投资收益-19.2万元，财务费用787.8万元，毛利率63.86%。财报数据概要请见下图:本文数据来源于澳华内镜2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429263","title":"澳华内镜（688212）披露2026年半年度报告，8月19日股价下跌4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429263?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:27","pubTimestamp":1787149633,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，澳华内镜报收于29.43元，较前一交易日下跌4.14%，最新总市值为39.63亿元。该股当日开盘30.45元，最高30.82元，最低29.27元，成交额达1.03亿元，换手率为2.56%。近日，上海澳华内镜股份有限公司披露2026年半年度报告。本报告期实现营业收入279,529,566.56元，同比增长7.37%；利润总额为-101,150,650.48元，归属于上市公司股东的净利润为-85,619,640.22元；归属于上市公司股东的扣除非经常性损益的净利润为-88,058,511.51元。研发投入占营业收入的比例为25.19%，较上年同期下降3.16个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658920380","title":"8月12日澳华内镜涨6.68%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658920380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658920380?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:32","pubTimestamp":1786523551,"startTime":"0","endTime":"0","summary":"证券之星消息，8月12日澳华内镜涨6.68%，收盘报31.8元，换手率6.42%，成交量8.64万手，成交额2.73亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.27亿元，最新净值1.9464，较上一交易日上涨0.26%，近一年下跌2.51%。圆信永丰医药健康A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200027622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["150219","688212","BK1515","159938","BK0251","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658989071","title":"澳华内镜：ERCP手术机器人已进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989071","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658989071?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:39","pubTimestamp":1786351149,"startTime":"0","endTime":"0","summary":"证券之星消息，澳华内镜(688212)08月10日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，请问贵司的手术机器人是否为创新医疗器械？目前该手术机器人享受何种政策？这种政策是否可以和创新药的政策相比？澳华内镜回复：您好，ERCP手术机器人已进入创新医疗器械特别审查程序，在注册申报时将获得优先办理的权益，可有效缩短产品注册周期，加快产品的上市速度。详情见2026年5月8日公司对外披露的公司公告。感谢您对澳华内镜的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000020584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK0251","BK1583","BK1100","BK1574","09996","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657156966","title":"澳华内镜获得发明专利授权：“力反馈调节装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657156966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657156966?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:52","pubTimestamp":1785873175,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示澳华内镜新获得一项发明专利授权，专利名为“力反馈调节装置”，专利申请号为CN202111659225.4，授权日为2026年8月4日。本发明提供的力反馈调节装置，通过对反馈力合理调节，可使内窥镜在人体内活动时易于掌控，同时，避免了内窥镜在人体内活动时力度过大，导致人体出现不适的反应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500005906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657879565","title":"澳华内镜新注册《澳华AQ-400系列电子内窥镜系统软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2657879565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657879565?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:29","pubTimestamp":1785868153,"startTime":"0","endTime":"0","summary":"证券之星消息，近日澳华内镜（688212）新注册了《澳华AQ-400系列电子内窥镜系统软件V1.0》项目的软件著作权。今年以来澳华内镜新注册软件著作权6个。结合公司2025年年报财务数据，2025年公司在研发方面投入了1.47亿元，同比减10.14%。通过天眼查大数据分析，上海澳华内镜股份有限公司共对外投资了9家企业，参与招投标项目978次；财产线索方面有商标信息35条，专利信息294条，著作权信息19条；此外企业还拥有行政许可466个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656395674","title":"澳华内镜新注册《澳华AQ-200系列电子内窥镜系统软件V1.1》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2656395674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656395674?lang=zh_cn&edition=full","pubTime":"2026-08-01 02:20","pubTimestamp":1785522023,"startTime":"0","endTime":"0","summary":"证券之星消息，近日澳华内镜（688212）新注册了2个项目的软件著作权，包括《澳华AQ-200系列电子内窥镜系统软件V1.1》、《澳华AQ-100系列电子内窥镜系统软件V1.1》等。今年以来澳华内镜新注册软件著作权5个。结合公司2025年年报财务数据，2025年公司在研发方面投入了1.47亿元，同比减10.14%。通过天眼查大数据分析，上海澳华内镜股份有限公司共对外投资了9家企业，参与招投标项目978次；财产线索方面有商标信息35条，专利信息294条，著作权信息19条；此外企业还拥有行政许可466个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100000570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653762984","title":"股市必读：澳华内镜（688212）7月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653762984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653762984?lang=zh_cn&edition=full","pubTime":"2026-07-23 01:24","pubTimestamp":1784741054,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，澳华内镜报收于25.38元，下跌2.23%，换手率2.0%，成交量2.7万手，成交额6912.88万元。董秘最新回复投资者： 董秘您好，我是一名财经博主，我注意到：贵公司过去五年加总的实际所得税率位于行业最低10%。当日关注点交易信息汇总：7月22日主力资金净流出610.91万元，游资资金净流入478.71万元，散户资金净流入132.21万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300001410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653673478","title":"澳华内镜创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2653673478","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653673478?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:15","pubTimestamp":1784700939,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152405","title":"7月17日澳华内镜跌7.46%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652152405?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:24","pubTimestamp":1784276674,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日澳华内镜跌7.46%，收盘报26.8元，换手率3.48%，成交量4.68万手，成交额1.28亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共22家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值3.7269，较上一交易日上涨0.34%，近一年上涨10.42%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651016146","title":"澳华内镜新注册《澳华电子内窥镜系统软件（AQ-120系列）V1.1》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2651016146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651016146?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:24","pubTimestamp":1783967053,"startTime":"0","endTime":"0","summary":"证券之星消息，近日澳华内镜（688212）新注册了《澳华电子内窥镜系统软件（AQ-120系列）V1.1》项目的软件著作权。今年以来澳华内镜新注册软件著作权3个。结合公司2025年年报财务数据，2025年公司在研发方面投入了1.47亿元，同比减10.14%。通过天眼查大数据分析，上海澳华内镜股份有限公司共对外投资了9家企业，参与招投标项目970次；财产线索方面有商标信息35条，专利信息293条，著作权信息16条；此外企业还拥有行政许可466个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400001722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","BK0251","159180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650342551","title":"澳华内镜新注册《澳华AQ-300系列电子内窥镜系统软件V1.1》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2650342551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650342551?lang=zh_cn&edition=full","pubTime":"2026-07-11 02:33","pubTimestamp":1783708389,"startTime":"0","endTime":"0","summary":"证券之星消息，近日澳华内镜（688212）新注册了2个项目的软件著作权，包括《澳华AQ-300系列电子内窥镜系统软件V1.1》、《澳华电子内窥镜系统软件（OR系列）V1.1》等。今年以来澳华内镜新注册软件著作权2个。结合公司2025年年报财务数据，2025年公司在研发方面投入了1.47亿元，同比减10.14%。通过天眼查大数据分析，上海澳华内镜股份有限公司共对外投资了9家企业，参与招投标项目970次；财产线索方面有商标信息35条，专利信息293条，著作权信息16条；此外企业还拥有行政许可466个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071100000486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688212","159180","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791962912912,"stockEarnings":[{"period":"1week","weight":-0.0622},{"period":"1month","weight":-0.0548},{"period":"3month","weight":-0.0672},{"period":"6month","weight":-0.2446},{"period":"1year","weight":-0.4838},{"period":"ytd","weight":-0.3967}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0628},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.0423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海澳华内镜股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"7576人(较上一季度增加13.50%)","perCapita":"17775股","listingDate":"2021-11-15","address":"上海市闵行区光中路133弄66号","registeredCapital":"13466万元","survey":" 上海澳华内镜股份有限公司的主营业务是电子内窥镜设备及内窥镜诊疗手术耗材研发、生产和销售。公司的主要产品是内镜主机（含图像处理器和光源）、内镜镜体、内镜周边设备、非血管支架、基础类耗材。","listedPrice":22.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"澳华内镜(688212)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供澳华内镜(688212)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"澳华内镜,688212,澳华内镜股票,澳华内镜股票老虎,澳华内镜股票老虎国际,澳华内镜行情,澳华内镜股票行情,澳华内镜股价,澳华内镜股市,澳华内镜股票价格,澳华内镜股票交易,澳华内镜股票购买,澳华内镜股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"澳华内镜(688212)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供澳华内镜(688212)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}